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INTRODUCTION
Image-guided percutaneous transthoracic needle biopsy 
(PTNB) is a minimally invasive tissue sampling procedure 
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Percutaneous transthoracic needle biopsy (PTNB) is one of the essential diagnostic procedures for pulmonary lesions. Its role 
is increasing in the era of CT screening for lung cancer and precision medicine. The Korean Society of Thoracic Radiology 
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provides 39 recommendations for the following four main domains of 12 key questions: the indications for PTNB, pre-procedural 
evaluation, procedural technique of PTNB and its accuracy, and management of post-biopsy complications. We hope that these 
recommendations can improve the diagnostic accuracy and safety of PTNB in clinical practice and promote standardization 
of the procedure nationwide.
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for the pathologic diagnosis of peripheral lung lesions. 
Image-guided PTNB has been performed since the 1960s 
(1); however, its first modern practice guideline was 
established by the British Thoracic Society (BTS) in 2003 
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(2). The introduction of lung cancer screening with low-
dose computed tomography (CT) (3-5) and the evolving 
field of precision medicine for lung cancer in the 2010s (6) 
are expanding the role of PTNB in lung cancer diagnostics. 
Nevertheless, the 2003 BTS guideline remains the sole 
guideline dedicated to PTNB. Wide variations in domestic 
practice patterns of PTNB were reported among surveyed 
radiologists in Korea (7), the United States (8), and the 
United Kingdom (9). The lack of an up-to-date guideline 
for PTNB may be responsible for these variations in 
practice, potentially hampering the delivery of standardized 
diagnoses and management of lung cancer. Therefore, we 
embarked on a project to develop the first evidence-based 
clinical practice guideline for PTNB in Korea by adapting 
pre-existing guidelines to improve the quality of PTNB in 
daily practice and promote standardization of the procedure 
nationwide.
Committee Composition
The working group comprised 14 thoracic radiologists 
from the Korean Society of Thoracic Radiology (KSTR). 
The development committee included the working group 
members, an expert respiratory physician, an oncologist, 
a thoracic surgeon, and a clinical guideline methodologist 
who supported the planning of the overall process and 
guideline methodology. All the working group members 
participated in the development of the guidelines, in which 
key questions were assigned (Supplementary Table 1). 
Adaptation Process of Pre-Existing Guidelines
Our guidelines development process employed the 
guideline adaptation methodology of the Korean Society 
of Radiology and the National Evidence-Based Healthcare 
Collaborating Agency (10) while following the Reporting 
Items for Practice Guidelines in Healthcare Statement (11). 
Key Questions
The working group had an offline meeting to discuss and 
list questions that should be addressed in the guidelines. 
The tentative list of key questions was circulated to 
working group members after meeting and debated online 
to prioritize the questions until consensus was reached. 
The four main domains for key questions addressed the 
indications for PTNB, pre-procedural evaluation, procedural 
technique of PTNB and its accuracy, and management of 
post-biopsy complications. For each domain, three key 
questions were specified, as follows: 
1) What are the Indications for PTNB for Lung Lesions? 
1-1) What are the conventional indications and general 
factors for considering PTNB?
1-2) What are the upcoming indications for PTNB in the 
era of personalized medicine? 
1-3) What are the contraindications for PTNB? 
2) Which Laboratory and Imaging Evaluations are 
Appropriate for Patients before PTNB? 
2-1) What kinds of laboratory tests are required prior to 
PTNB? 
2-2) Should a pulmonary function test be performed prior 
to PTNB? 
2-3) Which imaging examinations should be performed 
prior to PTNB?
3) What are the Appropriate Techniques for PTNB of Lung 
Lesions? 
3-1) How accurate should PTNB be?
3-2) How should interventionists choose the imaging 
guidance modality for PTNB? 
3-3) Which needle size, how many samples, and which 
technique (biopsy vs. aspiration) should be used for PTNB?
4) What is the Appropriate Management of Acute PTNB-
Related Complications? 
4-1) What is the appropriate management of 
pneumothorax? 
4-2) What is the appropriate management of hemoptysis? 
4-3) What is the appropriate management of air embolism 
and hemothorax?
Search for Guidelines
To identify relevant guidelines, a study coordinator 
performed systematic literature searches of international 
databases up to August 2018, including the Ovid-
MEDLINE, Ovid-EMBASE, Guidelines International Network, 
Cochrane Library, and major domestic databases, including 
KoreaMed, KMBASE, and Korean Medical Guidelines and 
Information (Supplementary Table 2). The searches were 
supplemented by screening the bibliographies of retrieved 
publications.
Selection of Searched Guidelines
A total of 910, 1033, 344, and 466 publications 
were identified in the initial searches for the main 
domains of key questions 1, 2, 3, and 4, respectively. 
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The appropriateness of the identified publications was 
assessed by three members per key question: the members 
independently selected guidelines based on the predefined 
inclusion and exclusion criteria, followed by establishing a 
consensus through discussion under the supervision. After 
excluding duplicates and performing an initial screening of 
titles and abstracts with a subsequent full-text review, the 
working group included 29, 4, 15, and 6 guidelines for the 
evidence synthesis of the four main domains, respectively 
(Supplementary Fig. 1).
Quality Appraisal of the Guidelines
The working group members reviewed the quality of the 
selected guidelines using the Korean Appraisal of Guidelines 
for Research and Evaluation II tool. We applied the 
following criteria for final inclusion: 1) guidelines with a 
mean overall quality score of 50 or higher by all reviewers; 
2) guidelines with a mean recommendation score of 50 or 
higher by the reviewers assigned to each key question. The 
median number of participating reviewers for assessing 
the overall quality was 8 per guideline, and the number 
of reviewers for key questions 1 to 4 was 4, 3, 4, and 3 
members, respectively. After these processes, 11, 7, 1, and 
4 guidelines were finally included for key questions 1 to 4, 
respectively (Supplementary Table 3).
Grading the Level of Evidence and Drafting the 
Recommendation Document
The working group members reviewed the evidence in 
the literature that supported the recommendations of 
the included guidelines. The members graded the level 
of evidence of each guideline based on the evidence 
level criteria of the Korean Clinical Imaging Guidelines 
to create an evidence table (Table 1, Supplementary 
Table 4) (10). A draft version of the recommendation 
document was produced based on the evidence table, then 
reviewed by the development committee, resulting in 39 
recommendations in four key questions. The final level of 
evidence and grade of recommendation was determined by 
the consensus of the development committee and working 
group members. 
Finalizing the Recommendation Document
The two-round Delphi method was used for formal 
consensus. The recommendation document with supporting 
materials was circulated to working group members via 
email. The members independently graded the degree of 
agreement in each recommendation using a 9-point scale: 
1 to 3, inappropriate; 4 to 6, uncertain; 7 to 9, appropriate 
recommendation. We adopted the recommendations for 
which more than two-thirds of the members assigned 
scores of 7 or higher. Among the 39 recommendations, 35 
recommendations were adopted in the first round, and the 
other four recommendations were adopted in the second 
round after the modification of tone and expression. The 
appropriateness score for the accepted recommendations 
was 7.0–9.0 (standard deviation: 0.4–2.1).
External Review and Approval of the Clinical Guideline
The final recommendations were reviewed by the core 
members of the KSTR and relevant Korean Academic 
Societies, including the Korean Academy of Tuberculosis and 
Table 1. Definition of Evidence Level and Recommendation Grading
Evidence Level Definition
High (I) Results are from appropriately designed experiments with low risk of bias
Moderate (II) Results are from appropriately designed experiments with intermediate risk of bias
Low (III) Results are from inappropriately designed experiments, or risk of bias is high
Very low (IV) Results are from inappropriately designed experiments, or risk of bias is very high
Recommendation Grading Definition
A This procedure has enough evidence to support desired effect, and therefore, is recommended
B
This procedure has intermediate to enough level of evidence to support desired effect and 
  can be provided selectively based on expert’s judgment
C
This procedure has enough evidence to support non-desired effect, and therefore, is not 
  recommended
D
This procedure does not have enough evidence to either support or reject effectiveness and 
  have very low level of certainty for desired effect requiring further research





Respiratory Disease, the Korean Association of Lung Cancer, 
the Korean Society of Medical Oncology, and the Korean 
Society for Thoracic and Cardiovascular Surgery. Feedbacks 
from the societies were evaluated and reflected in the 
practice guidelines as appropriate.
Recommendations, Summary of Guidelines, and 
Comments
The summary of the recommendations for the key 
questions is presented in Table 2. 
[Recommendation 1-1-1]
- We recommend assessing the risk of malignancy of 
pulmonary lesions before performing a biopsy. 
(recommendation grade A, evidence level III)
[Recommendation 1-1-2]
- We suggest performing a biopsy of pulmonary lesions 
that show definite growth.
(recommendation grade B, evidence level III)
[Recommendation 1-1-3]
- We suggest performing a biopsy of multiple nodular 
lesions of unknown etiology.
(recommendation grade B, evidence level III)
[Recommendation 1-1-4]
- We suggest performing a biopsy of persistent focal 
infiltrates of unknown etiology.
(recommendation grade B, evidence level III)
[Recommendation 1-1-5]
- We recommend assessing the risks and benefits of a 
biopsy procedure before performing the biopsy.
(recommendation grade A, evidence level II)
[Recommendation 1-1-6]
- We recommend evaluating the persistence of subsolid 
lesions by performing a follow-up CT scan 6–12 months 
later for pure ground-glass lesions, and 3–6 months later 
for part-solid lesions.
(recommendation grade A, evidence level II)
[Recommendation 1-1-7]
- We suggest that a biopsy may be considered for 
persistent or growing part-solid lesions larger than 15 mm 
overall and for those with a solid portion that is 8 mm or 
larger in diameter.
(recommendation grade B, evidence level II)
Remark: if a persistent or growing part-solid lesion is 
strongly suspected to be lung cancer, it is possible to 
proceed directly to surgical resection without PTNB.
Summary of Guidelines and Comments
The 2013 American College of Chest Physicians (ACCP) 
and 2015 BTS guidelines recommended assessing the 
pretest probability of malignancy when any diagnostic 
interventions, including PTNB, are applied for an 
indeterminate pulmonary nodule and when clinicians 
interpret biopsy results (12, 13) (Supplementary Table 4). A 
few risk prediction models for managing pulmonary nodules 
have been developed and validated (12, 13). Of these 
models, the Brock model generally provides the highest 
predictability of malignancy (13, 14). The Brock model 
calculates the estimated probability of malignancy for a 
pulmonary nodule based on the patient’s age, sex, family 
history of lung cancer, emphysema, nodule size, location 
of the nodule, nodule type (solid, part-solid, ground-glass 
nodule), nodule count, and spiculation. A negative biopsy 
result for malignancy must be cautiously interpreted, given 
the pretest probability of malignancy. If the biopsy result 
is negative for malignancy despite a high probability of 
malignancy (13), a repeated biopsy can be considered. 
A growing pulmonary nodular lesion is one of the main 
indications of PTNB in several guidelines (2, 13, 15, 16). 
Multiple nodular lesions of unknown etiology are another 
indication of PTNB (2). PTNB is also applicable to persistent 
focal infiltrates of unknown etiology when other non-
invasive or minimally invasive diagnostic procedures fail to 
make a diagnosis (2). PTNB is preferentially recommended 
for peripheral pulmonary lesions, which are likely to be 
inaccessible with a bronchoscopic approach (2, 12, 17).
The risk-benefit assessment of PTNB is presented in 
several guidelines as a fundamental step before performing 
the procedure (2, 12, 15, 18-20). PTNB is regarded to be 
generally safe, but complications of the procedure may 
occur. The risk of complications differs across patients, 
characteristics of the pulmonary lesions, and procedures. 
Accordingly, the benefits and risks of PTNB are assessed 
on an individual basis before performing PTNB, along with 
a consideration of other alternative diagnostic procedures 
that may be safer than PTNB. Detailed information about 
specific complications is presented in other parts of the 
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Key Question 1. What are the indications for PTNB for lung lesions? 
1-1) What are the conventional indications and general factors for considering PTNB?
- We recommend assessing the risk of malignancy of pulmonary lesions before performing a biopsy A III
- We suggest performing a biopsy of pulmonary lesions that show definite growth B III
- We suggest performing a biopsy of multiple nodular lesions of unknown etiology B III
- We suggest performing a biopsy of persistent focal infiltrates of unknown etiology B III
-  We recommend assessing the risks and benefits of a biopsy procedure before performing the  
  biopsy 
A II
-  We recommend evaluating the persistence of subsolid lesions by performing a follow-up CT scan 
  6–12 months later for pure ground-glass lesions, and 3–6 months later for part-solid lesions
A II
-  We suggest that biopsy may be considered for persistent or growing part-solid lesions larger  
  than 15 mm overall and for those with a solid portion that is 8 mm or larger in diameter
B II
    (remark: if a persistent or growing part-solid lesion is strongly suspected to be lung cancer, 
    it is recommended to proceed directly to surgical resection without PTNB)
1-2) What are the upcoming indications for PTNB in the era of personalized medicine? 
-  We recommend performing a biopsy to acquire a tumor specimen for molecular profiling of lung  
  cancer or intrathoracic metastasis
A I
- We recommend performing a biopsy according to the patient’s desire or clinical situation A III
- We recommend a multidisciplinary discussion to determine the necessity and site of the biopsy A III
1-3) What are the contraindications for PTNB? 
-  We recommend not performing a biopsy in the following circumstances, which are absolute  
  contraindications 
A III
1) Patients who do not provide informed consent
2) Pulmonary vascular lesions
-  We suggest that PTNB should be carefully considered in the following circumstances based on  
  a multidisciplinary risk-benefit assessment 
B III
1)  Patients with respiratory failure or with a predicted forced expiratory volume in 1 second  
  of less than 35%
2) Patients on mechanical ventilation
3) Patients with bleeding tendency or coagulopathy
4) Patients with pulmonary arterial or venous hypertension
5) Patients who underwent pneumonectomy or functionally have a single lung
6) Uncooperative patients
Key Question 2. Which laboratory and imaging evaluations are appropriate for patients before PTNB?
2-1) Which laboratory tests are required prior to PTNB?
-  We recommend checking hematocrit, prothrombin time, activated partial thromboplastin time,  
  and platelet count before performing the biopsy
A II
- We recommend withholding anticoagulants before performing the biopsy A II
2-2) Should a pulmonary function test be performed prior to PTNB?
-  We suggest performing a pre-procedural pulmonary function test in patients suspected of having  
  severe chronic obstructive pulmonary disease 
B III
-  We recommend a multidisciplinary discussion before performing PTNB in patients suspected  
  of having severe chronic obstructive pulmonary disease
A III
2-3) Which imaging examinations should be performed prior to PTNB procedures?
-  We recommend obtaining chest CT images of sufficient quality for planning the biopsy, possibly  
  with contrast enhancement 
A II
-  We suggest using an 18F-fluoro-deoxyglucose PET scan to determine the biopsy site for  






It is recommended to check the persistence of subsolid 
lesions before considering PTNB (12, 16), as a substantial 
proportion of subsolid lesions are transient (21). If 
a lesion persists, the 2013 ACCP and 2017 Fleischner 
guidelines recommend positron emission tomography (PET), 
nonsurgical biopsy, or surgical biopsy for a part-solid lesion 
with a solid portion larger than 8 mm (16), or a part-solid 






Key Question 3. What are the appropriate techniques for PTNB of lung lesions?
3-1) How accurate should PTNB be?
-  We recommend that the sensitivity and specificity of the biopsy for malignancy should be higher  
  than 85% and 90%, respectively
A II
-  We recommend minimizing non-diagnostic results and maintaining the proportion of insufficient 
  biopsy specimens as less than 10% of biopsies
A II
3-2) How should interventionists choose the guidance modality for PTNB?
-  We recommend primary utilization of fluoroscopic or CT-based guidance modalities for the biopsy,  
  including cone-beam CT and CT fluoroscopy
A II
-  We recommend that ultrasonography can be considered as the primary guidance modality  
  for subpleural pulmonary lesions abutting the chest wall
A II
-  We suggest that CT-based guidance modalities or multi-planar reconstruction can be considered  
  for pulmonary lesions 2 cm or smaller to increase the diagnostic accuracy of PTNB
B III
3-3)  Which needle size, how many samples, and which technique (biopsy vs. aspiration) should  
  be used for PTNB?
-  We recommend selecting either needle aspiration or cutting biopsy given the availability  
  of cytopathologists, the risk of malignancy, lesion diameter, required amount of tissue  
  specimens, and the interventionist’s experience
A II
-  We recommend determining the needle gauge and the number of samples based on the difficulty  
  and risk of the biopsy procedure, the gross quality of the biopsy specimens, and the need for  
  a subsequent examination
A II
Key Question 4. What is the appropriate management of acute PTNB-related complications?
4-1) What is the appropriate management of pneumothorax?
-  We recommend assessing the risk of pneumothorax before performing a biopsy and minimizing  
  the risk of pneumothorax during the procedure
A II
-  We recommend evaluating the occurrence of pneumothorax using chest radiographs or  
  the guidance modality by an interventionist after performing the biopsy
A II
-  We recommend determining the necessity of chest tube insertion by considering the status  
  of the patient, amount of pneumothorax, and medical availability
A II
4-2) What is the appropriate management of hemoptysis?
-  When hemoptysis occurs, we recommend monitoring vital signs and blood oxygen saturation  
  levels, along with assessing the amount of hemoptysis
A II
-  In cases of mild hemoptysis, we recommend conservative management with biopsy-site-down  
  positioning
A II
-  When massive hemoptysis occurs, we recommend supplying oxygen to maintain blood oxygen  
  saturation, along with considering single-lumen endotracheal tube insertion
A II
4-3) What is the appropriate management of air embolism and hemothorax? 
-  When systemic air embolism occurs, we recommend supplying oxygen at as high a concentration  
  as possible, including hyperbaric oxygen therapy, and anticonvulsants, if needed
A III
-  When a large amount of hemothorax occurs, we recommend conservative management,  
  while contacting clinicians such as thoracic or general surgeons and interventional radiologists
A III
CT = computed tomography, PTNB = percutaneous transthoracic needle biopsy
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lesion larger than 15 mm (12). Persistent subsolid lesions 
represent a spectrum of disease from atypical adenomatous 
hyperplasia to invasive lung adenocarcinoma (22). When the 
PTNB result indicated a preinvasive atypical adenomatous 
hyperplasia, approximately 90% of the lesions were found 
to be adenocarcinoma upon resection (23). Furthermore, 
the diagnostic accuracy of pre-surgical PTNB followed by 
resection was comparable to that of surgical resection 
based on CT analysis without PTNB (24). Considering the 
findings above, subsolid lesions strongly suspected to be 
lung adenocarcinoma can cautiously be advanced to surgical 
resection without PTNB.
[Recommendation 1-2-1]
- We recommend performing a biopsy to acquire a 
tumor specimen for molecular profiling of lung cancer or 
intrathoracic metastasis.
(recommendation grade A, evidence level I)
[Recommendation 1-2-2]
- We recommend performing a biopsy according to the 
patient’s desire or clinical situation.
(recommendation grade A, evidence level III)
[Recommendation 1-2-3]
- We recommend a multidisciplinary discussion to 
determine the necessity and site of the biopsy.
(recommendation grade A, evidence level III)
Summary of Guidelines and Comments
The 2013 ACCP guideline contained a recommendation 
about obtaining adequate tissue via nonsurgical biopsy 
for molecular analysis (15, 18) (Supplementary Table 4). 
The same recommendation was made in the 2011 National 
Institute for Health and Care Excellence (NICE) guideline 
(25) and the 2014 Scottish Intercollegiate Guidelines 
Network (SIGN) guideline (19). The 2018 European 
Society for Medical Oncology (ESMO) guideline specified 
particular mutations for molecular profiling, including 
epidermal growth factor receptor mutations, the T790M 
mutation, anaplastic lymphoma kinase rearrangement, ROS1 
rearrangement, BRAF V600 mutation, and programmed cell 
death ligand 1 expression (20). Decisions regarding the 
choice of procedure could be made depending upon the 
patient’s desire and a multidisciplinary discussion (12, 16). 
Molecular profiling is an essential step to provide the 
standard of care for patients with solid metastatic tumors 
(26). The reimbursement of targeted drugs usually requires 
information on the mutational status of the malignancy, 
and patients sometimes are willing to undergo PTNB for a 
mutational analysis despite an a priori known histologic 
diagnosis (27). As the genetic mutational profile of a 
tumor can change after a targeted therapy, PTNB of the 
same lesion can be repeated after treatment. Repeated 
PTNB for molecular profiling is typically defined as a 
rebiopsy, whereas a repeated biopsy refers to a repeated 
PTNB due to diagnostic failure of the initial PTNB (28). 
In the literature, 78.8–90.0% of rebiopsy specimens were 
adequate for molecular analysis, with an acceptable range 
of complication rates, from 4.0–25.7% (29-33). For the 
analysis of programmed death-ligand 1 (PD-L1) expression, 
PTNB provided adequate specimens in 96.4% of biopsies, 
with a complication rate of 28.4% (34). As it is important 
to target viable tumor tissue in rebiopsies (33), advanced 
imaging studies, including contrast-enhanced CT scans, 
PET scans, or diffusion-weighted or dynamic contrast 
MRI, can be performed before PTNB to distinguish viable 
tumor tissue from areas of necrosis, fibrotic tissue, or 
post-radiation changes. When selecting the biopsy target 
among multiple lesions, the primary tumor and metastatic 
lesions are regarded as equally suitable (35). A core needle 
biopsy is preferred over fine-needle aspiration for molecular 
analysis to obtain enough tumor tissue. If a tissue sample 
is obtained by fine-needle aspiration, it is desirable to 
assure the adequacy of tumor tissue by performing an on-
site evaluation of aspirated tissue (35).
[Recommendation 1-3-1]
- We recommend not performing a biopsy in 
the following circumstances, which are absolute 
contraindications.
1) Patients who do not provide informed consent
2) Pulmonary vascular lesions
(recommendation grade A, evidence level III)
[Recommendation 1-3-2]
- We suggest that PTNB should be carefully 
considered in the following circumstances based on a 
multidisciplinary risk-benefit assessment.
1) Patients with respiratory failure or with a predicted 
forced expiratory volume in 1 second (FEV1) of less than 
35%
2) Patients on mechanical ventilation




4) Patients with pulmonary arterial or venous 
hypertension
5) Patients who underwent pneumonectomy or 
functionally have a single lung
6) Uncooperative patients
(recommendation grade B, evidence level III)
Summary of Guidelines and Comments
The contraindications of PTNB can be categorized into 
absolute and relative contraindications. It is mandatory 
to obtain informed consent from the patient with a 
sufficient explanation of the benefits and potential risks 
of the procedure (2). PTNB is contraindicated if consent 
is not obtained. Vascular lesions, including pulmonary 
artery aneurysm or arteriovenous malformation, are 
absolute contraindications of PTNB. Interventionists should 
thoroughly evaluate preoperative CT images to avoid 
causing massive hemoptysis when performing PTNB due to 
vascular injury (36).
Relative contraindications of PTNB include respiratory 
failure or a predicted FEV1 of less than 35%, mechanical 
ventilation, bleeding tendency, coagulopathy, pulmonary 
arterial or venous hypertension, single lung (anatomically 
or functionally), and uncooperative patient. Thoracic 
interventionists must carefully consider whether to perform 
this procedure based on a multidisciplinary risk-benefit 
assessment (2). The minimum lung function required for 
PTNB is not clearly defined, but a threshold of a predicted 
FEV1 of 35% is commonly used (2). PTNB in patients on 
mechanical ventilation requires a careful approach, as 
mechanical ventilation increases both the difficulty of the 
procedure and the risk of pneumothorax and air embolism 
(37). A moderate or higher risk of bleeding tendency and 
coagulation abnormalities should be corrected before the 
procedure (2). 
Pulmonary artery or venous hypertension is traditionally 
recognized as a risk factor for bleeding after PTNB (2). 
However, the cutoff value of pulmonary arterial pressure as 
a contraindication of PTNB has rarely been specified. Right-
sided heart catheterization is the reference method for 
diagnosing pulmonary hypertension by measuring the mean 
pulmonary artery pressure, but this procedure is seldom 
performed before PTNB in clinical practice. An enlargement 
of the diameter of the main pulmonary artery to 2.95 cm or 
larger on pre-procedural CT can be used for assessing the 
presence of pulmonary hypertension if the information on 
the mean pulmonary artery pressure is not available (38). 
Conflicting reports exist regarding whether enlargement 
of the main pulmonary artery is a risk factor for severe 
parenchymal hemorrhage or hemoptysis after PTNB (39, 40).
Although a history of pneumonectomy has been 
regarded as an absolute contraindication to PTNB (41, 
42), Cronin et al. (43) reported that the success rate of 
PTNB, preferentially performed by needle aspiration, was 
86% (12 of 14) in a single lung in patients with a history 
of pneumonectomy. Pneumothorax occurred in 25% of 
patients, but all cases were asymptomatic and did not 
require further intervention. If an experienced practitioner 
prepares well and performs the procedure carefully based on 
a multidisciplinary risk-benefit assessment, percutaneous 
lung aspiration may be performed in those patients.
Finally, the safety and success of PTNB relies on patient 
coordination (2); in particular, the patient must maintain 
a stable position and comply with breathing instructions 
during the procedure. 
[Recommendation 2-1-1]
- We recommend checking hematocrit, prothrombin 
time, activated partial thromboplastin time, and platelet 
count before performing the biopsy. 
(recommendation grade A, evidence level II)
[Recommendation 2-1-1]
- We recommend withholding anticoagulants before 
performing the biopsy.
(recommendation grade A, evidence level II)
Summary of Guidelines and Comments
A pre-procedural laboratory evaluation for coagulopathy 
is required before PTNB (2). PTNB can be accompanied 
by bleeding in the lung parenchyma and along the needle 
track during or after the procedure. Bleeding can manifest 
as asymptomatic pulmonary parenchymal hemorrhage, 
hemoptysis, hemothorax, chest wall hematoma, and 
pulmonary artery pseudoaneurysm. However, mortality due 
to bleeding after PTNB is rare (44-46). PTNB is designated 
as an interventional procedure with a moderate risk of 
bleeding in the 2012 Society of Interventional Radiology 
guideline (47) and with a high risk of bleeding in the 
2019 Society of Interventional Radiology guideline (48). 
The international normalized ratio needs to be maintained 
below 1.5 (47, 48), and the minimum platelet count 
maintained at 70000/μL (47, 48). Impaired coagulation 
status and platelet counts need to be corrected as much as 
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possible if the above thresholds are not met. Clopidogrel 
may be withheld for five days before the procedure, 
according to the 2019 Society of Interventional Radiology 
guideline, while aspirin may not be required to be withheld 
(48). Regarding low-molecular weight-heparin, the last 1 or 
2 doses need to be withheld (47, 48). The 2019 guideline 
also emphasizes shared decision-making for planning peri-
procedural management and a balanced assessment of 
the risks of post-procedural bleeding and thromboembolic 
events (48). 
[Recommendation 2-2-1]
- We suggest performing a pre-procedural pulmonary 
function test in patients suspected of having severe 
chronic obstructive pulmonary disease.
(recommendation grade B, evidence level III)
[Recommendation 2-2-2]
- We recommend a multidisciplinary discussion before 
performing PTNB in patients suspected of having severe 
chronic obstructive pulmonary disease.
(recommendation grade A, evidence level III)
Summary of Guidelines and Comments
Patients with severe chronic obstructive pulmonary 
disease find it challenging to hold their breath during the 
PTNB procedure and are more vulnerable to respiratory 
failure than healthy patients if pneumothorax or hemoptysis 
occurs. The 2003 BTS guideline (2) recommends reviewing 
recent results of pulmonary function testing (spirometry) in 
all patients undergoing PTNB as part of the multidisciplinary 
risk-benefit assessment and avoiding biopsy in patients 
with an FEV1 below 35%. Nevertheless, no robust minimum 
threshold has yet been established for FEV1 to ensure the 
safety of PTNB in patients with severe chronic obstructive 
pulmonary disease (2). Concerning the practical point of 
view, it is necessary to perform a pulmonary function test 
before PTNB, as a post-biopsy complication can hinder an 
accurate measurement of baseline lung function that is 
essential for planning further management after a cancer 
diagnosis.
[Recommendation 2-3-1]
- We recommend obtaining chest CT images of sufficient 
quality for planning the biopsy, possibly with contrast 
enhancement.
(recommendation grade A, evidence level II)
[Recommendation 2-3-2]
- We suggest using an 18F-fluoro-deoxyglucose PET 
scan to determine the biopsy site for a pulmonary lesion 
suspected of having necrosis.
(recommendation grade B, evidence level III)
Summary of Guidelines and Comments
The pre-procedural planning of a PTNB procedure based 
on chest CT images is one of the most salient steps (2). 
A sufficient quality of chest CT images for planning the 
biopsy may be varyingly defined across interventionists. 
However, thin-section CT images without significant image 
noise or artifacts are generally preferred. The pre-procedural 
assessment includes 1) identifying alternative lesions 
outside the lung and safer alternative procedures than 
PTNB, 2) selecting the most appropriate imaging guidance 
modality for PTNB, and 3) planning the safest needle path 
for the PTNB procedure by reviewing the nodule location, 
characteristics, surrounding bronchovascular structures, 
fissure, and bullae (2). 
If a pulmonary lesion is accompanied by an 
extrapulmonary lesion, biopsying the extrapulmonary lesion 
should be considered first, and a bronchoscopic approach 
is preferable for a central pulmonary lesion (18, 19). If 
multiple pulmonary lesions exist, the target lesion can be 
chosen, primarily based on the size and location of the 
lesions. Larger and more superficial lesions are generally 
easier to be approached. 
Juxtapleural lesions are the most superficial, but 
PTNB of juxtapleural lesions may be challenging, as 
respiratory motions can cause dislocation of the biopsy 
needle, particularly for smaller lesions in the lower 
lobes. The number of pleural punctures and the length 
of the transparenchymal passage should be minimized. 
It is also vital for the trajectory of the biopsy needle to 
avoid the penetration of fissures and bullae, resulting 
in pneumothorax. If the target lesion abuts major 
cardiopulmonary structures, it is necessary to pre-
procedurally set a safety margin on the imaging guidance 
modality that must never be violated during the procedure. 
The visibility of the lesion on the guidance modality needs 
to be assessed (49). 
Contrast-enhanced CT images allow a clearer depiction 
of cystic or necrotic portions within a pulmonary lesion 
(50) and the nature of the lesion (e.g., pulmonary vascular 
malformation). The interventionist can also determine 




present within the lesion to avoid a potential penetration 
or cutting injury of the vessels during the procedure (36). 
PET could identify the metabolically active portion of a 
pulmonary lesion, likely yielding a definitive result (12). 
The introduction of visually or digitally co-registered PET 
scans improved the diagnostic accuracy of PTNB (51, 52).
[Recommendation 3-1-1]
- We recommend that the sensitivity and specificity of 
the biopsy for malignancy should be higher than 85% and 
90%, respectively.
(recommendation grade A, evidence level II)
[Recommendation 3-1-2]
- We recommend minimizing non-diagnostic results 
and maintaining the proportion of insufficient biopsy 
specimens as less than 10% of biopsies.
(recommendation grade A, evidence level II)
Summary of Guidelines and Comments
The accuracy of a PTNB is greatly affected by whether it 
was diagnostic or non-diagnostic. In general, diagnostic 
results correspond to malignancy or specific benign disease. 
Non-diagnostic results are usually categorized into three 
groups (53): non-specific benign results, atypical cells, 
and insufficient specimens. Non-specific benign results 
are defined as pathologic findings of a biopsy specimen 
suggestive of a benign pathologic nature without evidence 
of malignancy, but with insufficient information to render 
a specific diagnosis (54); this category includes acute 
or chronic non-specific inflammation, granulomatous 
inflammation, abscess, organizing pneumonia, and focal 
fibrosis. Atypical cells refer to a biopsy specimen containing 
atypical cells or a biopsy specimen that is suspicious for 
malignancy, but with insufficient information for a specific 
diagnosis. An insufficient specimen is defined as a biopsy 
specimen that only contains blood, necrotic tissue, normal 
lung parenchyma, or insufficient tissue for making any 
diagnosis. 
According to a previous meta-analysis (23), three-
fourths of PTNB procedures provide diagnostic results, while 
one-fourth of procedures are non-diagnostic (23). When 
diagnostic, the PTNB result tended to be consistent with 
the final diagnosis: malignancy rate when PTNB result was 
malignancy, 99.8%; malignancy rate when PTNBs result was 
specific benignity, 1.5%. However, the malignancy rates of 
non-diagnostic biopsy results significantly differ according 
to the category of the non-diagnostic biopsy result (55). 
On average, the malignancy rates of non-specific benign 
results, atypical cells, and insufficient specimens were 
20.6%, 91.1%, and 59.2%, respectively (23). In line with 
these findings, the 2013 ACCP and 2015 BTS guidelines 
emphasized that non-diagnostic biopsy results do not rule 
out the possibility of malignancy (12, 15, 56).
Several guidelines have provided a summary of the 
diagnostic accuracy of PTNB (13, 18, 19, 25), and a recent 
meta-analysis provided an up-to-date summary (23). In 
the meta-analysis, the pooled sensitivity and specificity of 
PTNB procedures reached 97% and 100%, respectively, when 
omitting PTNB procedures with an insufficient specimen 
(Supplementary Fig. 2) (23). However, when an insufficient 
specimen was considered a diagnostic failure, the pooled 
sensitivity and specificity of PTNB procedures were around 
90% (23). Diagnostic failure (i.e., false-positive, false-
negative, and non-evaluable results due to insufficient 
specimens) could occur more frequently in certain patients 
and lesions (e.g., patients with emphysema, lesions 
smaller than 2 cm, or subsolid lesions) with certain biopsy 
procedures (the use of fine-needle aspiration only without 
a biopsy, if the introducer needle is outside the target 
lesion, longer procedures) depending on the final pathology 
(lymphoma or benign disease) or if complications occur 
(alveolar hemorrhage) (55). 
The 2003 BTS guideline specified estimates of the 
accuracy of PTNB as follows: false positivity, less than 1%; 
the proportion of adequate biopsy samples, over 90%; and 
sensitivity for malignancy, 85–90% in lesions larger than 
2 cm; furthermore, it recommended setting standards for 
PTNB through auditing (2). Thoracic interventionists should 
be aware of the incidence and predictors of diagnostic 
and non-diagnostic results in their PTNB procedures. The 
interventionists should try to minimize non-diagnostic 
results, especially those due to insufficient specimens.
[Recommendation 3-2-1]
- We recommend primary utilization of fluoroscopic or 
CT-based guidance modalities for the biopsy, including 
cone-beam CT and CT fluoroscopy.
(recommendation grade A, evidence level II)
[Recommendation 3-2-2]
- We recommend that ultrasonography can be 
considered as the primary guidance modality for 
subpleural pulmonary lesions abutting the chest wall.
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(recommendation grade A, evidence level II)
[Recommendation 3-2-3]
- We suggest that CT-based guidance modalities 
or multi-planar reconstruction can be considered for 
pulmonary lesions 2 cm or smaller to increase the 
diagnostic accuracy of PTNB.
(recommendation grade B, evidence level III)
Summary of Guidelines and Comments
Thoracic interventionists can determine the guidance 
modality according to the availability of various modalities, 
experience and preference of the interventionists, lesion 
size, and location of the pulmonary lesion (2). Several 
guidelines have mentioned that PTNB can be performed 
under the guidance of fluoroscopy, CT, or ultrasonography, 
and did not recommend a uniform preferential guidance 
modality for PTNB in general (2, 13, 15, 18, 19, 25). The 
2003 BTS guideline (2) and the 2011 NICE guideline (25) 
recommended utilizing ultrasonography as a guidance 
modality when a pulmonary lesion abuts the chest wall. 
Compared with CT-guided biopsy, ultrasonography-guided 
biopsy provided a lower complication rate and shorter 
procedural time without ionizing radiation exposure, along 
with similar diagnostic accuracy (57-59). Conventional CT 
guidance with multi-planar reconstruction or cone-beam 
CT guidance may improve the diagnostic accuracy of PTNB, 
particularly for small pulmonary lesions (13). In a recent 
multicenter retrospective cohort study, the use of CT and 
cone-beam CT guidance reduced the diagnostic failure 
rate of PTNB (60), along with lowering the incidence of 
hemoptysis compared to fluoroscopic guidance (46). As 
fluoroscopy, CT, cone-beam CT, and CT fluoroscopy guidance 
are inevitably accompanied by ionizing radiation exposure 
to patients and/or interventionists, radiation exposure 
should be monitored and minimized during the procedure as 
much as possible (61, 62).
[Recommendation 3-3-1]
- We recommend selecting either needle aspiration or 
cutting biopsy given the availability of cytopathologists, 
the risk of malignancy, lesion diameter, required amount 
of tissue specimens, and the interventionist’s experience.
(recommendation grade A, evidence level II)
[Recommendation 3-3-2]
- We recommend determining the needle gauge and 
the number of samples based on the difficulty and risk 
of the biopsy procedure, the gross quality of the biopsy 
specimens, and the need for a subsequent examination.
(recommendation grade A, evidence level II)
Summary of Guidelines and Comments
Thoracic interventionists can choose the type of needle 
depending on their experience, available cytological 
support, and the location of the target lesion, along with 
emphasizing the importance of sufficient biopsy passes (2). 
In general, core needle biopsy obtains a larger amount of 
biopsy specimens than fine-needle aspiration. Core needle 
biopsy and fine-needle aspiration provide similar diagnostic 
accuracy for malignancy (2, 18). Nevertheless, the 
diagnostic accuracy for benign disease tends to be lower in 
fine-needle aspiration than in core needle biopsy (2, 18). 
The presence of on-site cytopathologists helps to achieve 
higher diagnostic accuracy with fine-needle aspiration (2). 
Most interventionists obtain at least two tissue samples (2). 
The diagnostic accuracy of PTNB increases cumulatively, 
but the magnitude of the incremental gain of accuracy is 
reduced as the number of tissue samples increases up to the 
third to fourth samples (63, 64). Theoretically, obtaining 
more samples may lead to a higher rate of complications. 
However, such a relationship has not been evident in the 
literature, except for the finding that a higher number of 
pleural passages results in more frequent pneumothorax 
(46). Differences in the needle gauge may result in a 
different rate of non-diagnostic results (55). 
[Recommendation 4-1-1]
- We recommend assessing the risk of pneumothorax 
before performing a biopsy and minimizing the risk of 
pneumothorax during the procedure.
(recommendation grade A, evidence level II)
[Recommendation 4-1-2]
- We recommend evaluating the occurrence of 
pneumothorax using chest radiographs or the guidance 
modality by an interventionist after performing the 
biopsy.
(recommendation grade A, evidence level II)
[Recommendation 4-1-3]
- We recommend determining the necessity of chest 
tube insertion by considering the status of the patient, 




(recommendation grade A, evidence level II)
Summary of Guidelines and Comments
Pneumothorax, which is the most frequent complication 
after PTNB, may necessitate tube drainage. National 
multicenter surveys or large cross-sectional analyses in the 
United Kingdom (5444 biopsies), Japan (9783 biopsies), 
Korea (10568 biopsies), and United States (15865 biopsies) 
reported pneumothorax rates of 15.0–35.0% and rates of 
pneumothorax requiring tube drainage of 3.1–6.6% (17, 
44-46). Higher rates of pneumothorax were associated 
with older age (46, 65), male sex (46, 66), smoking (46, 
65), emphysema (46, 67) (particularly emphysema along 
the needle path (66, 68)), a deep-seated lesion (46, 69), 
smaller lesion size (46, 65, 67), subpleural lesions (65, 
69), a higher number of pleural passages (46, 66), lateral 
pleural puncture, traversing a fissure with the biopsy needle 
(68), use of large coaxial stabilizing needle (70), lack of 
pleural thickening (68), no previous pulmonary surgery 
(71), lesions in the lower lobe (66, 71), a shallow pleural 
puncture angle (68), a wider trajectory angle (71, 72), 
less experienced interventionists (65), and the use of core 
needle biopsy compared to fine-needle aspiration (73). A 
few preventative measures can be applied to reduce the 
risk of pneumothorax after PTNB. A recent meta-analysis 
reported that normal saline tract sealant, a rapid needle-
out patient-rollover approach (74), and the use of a tract 
plug or blood patch reduced the likelihood of pneumothorax 
requiring tube drainage (75). One study reported that 
positioning the patient with the biopsy side down could 
reduce pneumothorax incidence after PTNB (76).
An upright chest radiograph should be obtained 
within a few hours after the biopsy to identify potential 
complications (2) and is sufficient to detect the majority 
of cases of post-biopsy pneumothorax (77). More than 90% 
of all pneumothoraces appeared within 3 to 4 hours of the 
PTNB, and most of the delayed pneumothoraces occurred 
within 24 hours after the procedure (78, 79). Female 
sex, absence of emphysema, and a larger target size were 
associated with the occurrence of delayed pneumothorax 
(78, 79). Patients should be informed of the risks of 
delayed pneumothorax after PTNB (2). A suitably qualified 
radiologist should review the post-biopsy chest radiograph. 
The management options include observation, air aspiration, 
and tube drainage. The management decision will be 
affected by factors such as the size of the pneumothorax, 
the patient’s condition (e.g., underlying disease such as 
COPD), and the patient’s symptoms and signs (the degree of 
hypoxemia and subjective pain) (2).
[Recommendation 4-2-1]
- When hemoptysis occurs, we recommend monitoring 
vital signs and blood oxygen saturation levels, along with 
assessing the amount of hemoptysis.
(recommendation grade A, evidence level II)
[Recommendation 4-2-2]
- In cases of mild hemoptysis, we recommend 
conservative management with biopsy-site-down 
positioning.
(recommendation grade A, evidence level II)
[Recommendation 4-2-3]
- When massive hemoptysis occurs, we recommend 
supplying oxygen to maintain blood oxygen saturation, 
along with considering single-lumen endotracheal tube 
insertion.
(recommendation grade A, evidence level II)
Summary of Guidelines and Comments
The pooled rates of pulmonary hemorrhage after CT-guided 
core needle biopsy and fine-needle aspiration were found 
to be 18.0% and 6.4%, respectively, and the pooled rates 
of hemoptysis were 4.1% and 1.6%, respectively (73). Risk 
factors affecting the incidence or severity of hemoptysis 
after PTNB include a deeper-seated location (39, 40, 46, 
65, 66, 69, 80), a small lesion (39, 46, 65, 80), a subsolid 
lesion (39, 40, 46, 66), a cavity (40), a lesion with an open 
bronchus sign (81), older age (39), female sex (39, 46, 80), 
dual-antiplatelet therapy (40, 80), the coaxial technique 
(39), core needle biopsy (46, 80), and a penetrating and 
cutting injury of bronchovascular structures (36). Conflicting 
reports exist about the relationship between enlargement of 
the main pulmonary artery diameter on CT and pulmonary 
hemorrhage or hemoptysis (39, 40). Hemoptysis developed 
less frequently using CT-based guidance modalities than 
when fluoroscopy was used (46). 
Hemoptysis is usually self-limiting. Most hemoptysis 
cases could be managed by maintaining the patient in 
the lateral decubitus position with the biopsy side down 
and providing appropriate reassurance (2). It is crucial to 
protect the airway and secure the unaffected lung from the 
lung where hemoptysis originates (82). Biopsy-site-down 
lateral positioning is effective for doing so. The patient’s 
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ability to expectorate aspirated blood is also salient for 
maintaining the airway (83). Massive, potentially fatal, 
hemoptysis may develop after PTNB. Massive hemoptysis 
is traditionally defined as an amount of hemoptysis of 600 
mL or larger within 24 hours (84). However, measuring 
the amount of hemoptysis is challenging in practice, and 
thoracic interventionists need to determine the severity 
of hemoptysis by systematically considering not only the 
volume of hemoptysis, but also the rate of bleeding, the 
degree of hemodynamic instability, oxygen desaturation 
(36), and the patient’s physiological reserves (83). It 
is essential to monitor vital signs and resuscitate the 
patient from oxygen desaturation via an oxygen supply in 
the biopsy-site-down position (2). If hemoptysis persists 
without cardiopulmonary compromise, CT angiography may 
be performed to identify the cause of massive hemoptysis 
(85), while maintaining the lateral positioning. Selective 
intubation into the unilateral bronchial main stem with an 
endotracheal tube, based on sufficient clinical expertise, can 
ensure that the unaffected lung is isolated from hemoptysis 
(2, 83). Rigid bronchoscopy, transcatheter arterial 
embolization, or surgical management may be introduced in 
some centers for managing massive hemoptysis that cannot 
be managed conservatively (83).
[Recommendation 4-3-1]
- When systemic air embolism occurs, we recommend 
supplying oxygen at as high a concentration as possible, 
including hyperbaric oxygen therapy, and anticonvulsants, 
if needed.
(recommendation grade A, evidence level III)
[Recommendation 4-3-2]
- When a large amount of hemothorax occurs, we 
recommend conservative management, while contacting 
clinicians such as thoracic or general surgeons and 
interventional radiologists.
(recommendation grade A, evidence level III)
Summary of Guidelines and Comments
In reports of thousands of PTNB procedures, the incidence 
of air embolism was 0.02–0.18% (44-46). Symptoms can 
occur suddenly during or after the procedure and can 
differ according to the location of air embolism (2). A 
post-procedural CT scan may help make a diagnosis of air 
embolism in the systemic arteries, including the coronary or 
cerebral arteries (86). Administration of oxygen at as high 
a concentration as possible is the most important step to 
relieve hypoxia and hypoxemia and facilitate the elimination 
of an air embolism (86). Hyperbaric oxygen therapy is 
regarded as the treatment of choice for arterial gas embolism 
(87, 88). The supine (86) or Trendelenburg position (89) 
is recommended in patients with arterial air embolism, 
although the best positioning has not been conclusively 
established. Whether to administer corticosteroid or aspirin 
treatment remains controversial (86). 
The incidence of hemothorax after PTNB has been 
reported to range from 0.09–0.57% (45, 46). If hemothorax 
develops after PTNB, thoracic interventionists need 
to manage patients conservatively and monitor the 
amount of hemothorax on serial chest radiographs, while 
correcting coagulopathy (2). If the hemothorax is large 
or continuously growing, CT angiography is an effective 
modality to evaluate the possibility of an iatrogenic injury 
of the intercostal or internal mammary arteries (90). 
Transcatheter artery embolization of the injured arteries 
is the first treatment option for iatrogenic intercostal or 
internal mammary arterial bleeding (91, 92). 
Considerations for Recommendations
Benefits and Harms
PTNB provides an accurate diagnosis of indeterminate 
pulmonary lesions. The overall complication rate is around 
25% or higher, but most of the complications can be 
conservatively managed. The occurrence of complications 
can prolong a patient’s hospital stay and increase medical 
costs. The use of fluoroscopic or CT-based guidance 
modalities for PTNB is accompanied by radiation exposure 
to patients and interventionists. The diagnostic accuracy, 
complication rate, and magnitude of the radiation dose can 
vary depending on the characteristics of the patient, lesion, 
procedure, and experience of the interventionist. Thoracic 
interventionists carefully perform PTNB based on a risk-
benefit assessment and the probability of malignancy.
Acceptability and Applicability
Most of the recommendations in the included guidelines 
were judged to be acceptable and applicable to domestic 
practice (Supplementary Table 4), except for the subsection 
regarding the indications of PTNB in the 2015 BTS guideline, 
which largely depend on the Brock model in clinical practice 






The mean estimations of the patient effective dose in the 
literature are as follows: fluoroscopic guidance, 0.029 mSv 
(93); CT guidance, 0.7 to 2.7 mSv (94, 95); cone-beam CT or 
CT fluoroscopic guidance, 7 mSv (66, 95). Ultrasonographic 
guidance is free of radiation exposure.
Limitation 
These guidelines have several limitations. First, the 
guidelines could not fully reflect the results of the up-to-
date literature, as it was based on an adaptation of pre-
existing guidelines relevant to PTNB with sufficient quality. 
In most of the included guidelines, PTNB was covered as 
one of the available options to diagnose a pulmonary lesion. 
We introduced the results of some recent investigations and 
meta-analyses for each key question, but the studies were 
not systematically searched and might be biased. Second, 
we could not reflect patients’ opinions on PTNB and their 
experiences during PTNB in the guideline, as the included 
guidelines rarely dealt with patients’ opinions. Although PTNB 
is generally well-tolerated, some patients could suffer from 
considerable pain and discomfort (96). Third, the guidelines 
did not address the risk of tumor implantation along the 
PTNB needle track in the pleural or chest wall, which is a rare 
but potentially long-term complication (97, 98). 
SUMMARY
We developed the first evidence-based clinical practice 
guideline for PTNB in Korea by adapting pre-existing 
guidelines. The guideline provides several recommendations 
for the following four main domains of key questions: 
indications for PTNB, pre-procedural evaluation, procedural 
technique of PTNB and its accuracy, and management 
of post-biopsy complications. We hope that these 
recommendations can improve the diagnostic accuracy 
and safety of PTNB in clinical practice and promote 
standardization of the procedure nationwide.
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